Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 2:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 83 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: L-dopa Clear all
Completed Phase 2 Interventional

Levetiracetam Treatment of L-dopa Induced Dyskinesias

NCT00076674
View directory record Official record
Conditions
Dyskinesias, Parkinson Disease
Interventions
Intravenous Levodopa
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Oct 17, 2026, 2:39 AM EDT
Withdrawn Phase 2 Interventional

A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration

NCT02873351
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
carbidopa-levodopa 25-100 mg, placebo for carbidopa-levodopa 25-100 mg
Drug
Lead sponsor
Snyder, Robert W., M.D., Ph.D., P.C.
Individual
Eligibility
50 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 5, 2019 · Synced Oct 17, 2026, 2:39 AM EDT
Active, not recruiting No phase listed Observational

A Pilot Study Using 18F-DOPA PET-guided Radiotherapy in Gliomas

NCT02104310
View directory record Official record
Conditions
Malignant Glioma
Interventions
Fluorine-18-L-dihydroxyphenylalanine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
7 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 17, 2026, 2:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dopaminergic Effects on Cortical Function in Tourette's (Levodopa Protocol)

NCT00634556
View directory record Official record
Conditions
Tourette Syndrome
Interventions
levodopa solution 2mg/ml for i.v. use, placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 12, 2018 · Synced Oct 17, 2026, 2:39 AM EDT
Terminated Phase 4 Interventional Results available

L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults

NCT03761030
View directory record Official record
Conditions
Major Depressive Disorder, Dysthymia, Depression
Interventions
L-DOPA, Placebo Oral Tablet
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
60 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Oct 17, 2026, 2:39 AM EDT
Completed Phase 2 Interventional

EMD 128130 for the Treatment of Parkinson's Disease

NCT00009048
View directory record Official record
Conditions
Parkinson's Disease
Interventions
EMD 128130, IV Levodopa
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 17, 2026, 2:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

PET Imaging of the Dopaminergic and Serotonergic Systems in Treated HIV Positive Subjects

NCT03581305
View directory record Official record
Conditions
Depression, HIV Infections, HIV-Associated Cognitive Motor Complex
Interventions
18F-FDOPA, 11C-DASB
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 17, 2026, 2:39 AM EDT
Recruiting Phase 1 Interventional

Diagnosis of Pheochromocytoma

NCT00004847
View directory record Official record
Conditions
Pheochromocytoma, Endocrine Disease, Endocrine Diseases
Interventions
([18F]-DOPA), ([18F]-6F-DA)
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
3 Years to 120 Years
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2048
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 17, 2026, 2:39 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Dopaminergic Dysfunction in Late-Life Depression

NCT04469959
View directory record Official record
Conditions
Late Life Depression, Cognitive Decline, Depressive Disorder, Treatment-Resistant, Levodopa, Gait Impairment
Interventions
L-Dopa, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
60 Years and older
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 17, 2026, 2:39 AM EDT
Recruiting Phase 4 Interventional

Dopaminergic Therapy for Anhedonia - 2

NCT06075771
View directory record Official record
Conditions
Anhedonia, Depression
Interventions
Carbidopa Levodopa, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
25 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 17, 2026, 2:39 AM EDT
Completed Early Phase 1 Interventional

A Targeted Amino Acid Supplement for People With Parkinson's Disease

NCT06954662
View directory record Official record
Conditions
Parkinson Disease, Idiopathic
Interventions
Amino acid supplement, Whey Protein Supplement, Isonitrogenous Placebo Supplement
Drug · Dietary Supplement
Lead sponsor
UConn Health
Other
Eligibility
55 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 17, 2026, 2:39 AM EDT
Not listed Phase 2 Interventional

Effect of L-Dihydoxyphenylserine on Locomotion, Postural Stability, and Fall Risk Reduction in Parkinson Disease

NCT02812147
View directory record Official record
Conditions
Parkinson Disease
Interventions
L-DOPS, Placebo
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
30 Years to 83 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 17, 2026, 2:39 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Trial of Levodopa in Angelman Syndrome

NCT01281475
View directory record Official record
Conditions
Angelman Syndrome
Interventions
Levodopa, Placebo Oral Capsule
Drug
Lead sponsor
Wen-Hann Tan
Other
Eligibility
4 Years to 12 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
7
States / cities
San Diego, California • San Francisco, California • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Oct 17, 2026, 2:39 AM EDT
Completed No phase listed Observational

Positron Emission Tomography (PET) Imaging in People With Gaucher Mutations

NCT00302146
View directory record Official record
Conditions
Parkinson Disease, Gaucher Disease
Interventions
15-0 H20
Drug
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years to 110 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 17, 2026, 2:39 AM EDT
Completed Phase 1 Interventional

A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder)

NCT02807675
View directory record Official record
Conditions
Parkinson's Disease
Interventions
CVT-301, LIP, Placebo
Drug · Other
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
30 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
11
States / cities
Fountain Valley, California • Boca Raton, Florida • Hallandale, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 17, 2026, 2:39 AM EDT
Completed No phase listed Observational

An Imaging Agent (Fluorodopa F 18) With Positron Emission Tomography/Magnetic Resonance Imaging for Assessing Treatment Response in Patients With High-Grade Soft Tissue Sarcomas

NCT05560009
View directory record Official record
Conditions
Recurrent Soft Tissue Sarcoma, Resectable Soft Tissue Sarcoma, Soft Tissue Sarcoma
Interventions
Fluorodopa F 18, Magnetic Resonance Imaging, Positron Emission Tomography, Radiation Therapy, Surgical Procedure
Drug · Procedure · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Oct 17, 2026, 2:39 AM EDT
Not yet recruiting Phase 1 Interventional

AAV2-hAADC for Parkinson's Disease (PDCS-01)

NCT07267065
View directory record Official record
Conditions
Parkinson's Disease (PD), Early Onset Parkinson Disease
Interventions
AAV2-hAADC
Drug
Lead sponsor
Krzysztof Bankiewicz
Other
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 17, 2026, 2:39 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced Dyskinesia

NCT01092065
View directory record Official record
Conditions
Parkinson's Disease
Interventions
AFQ056 with L-dopa, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
30 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Sunnyvale, California • Englewood, Colorado • Indianapolis, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Oct 17, 2026, 2:39 AM EDT
Completed No phase listed Observational

PET Scanning in Parkinson s Disease

NCT00024622
View directory record Official record
Conditions
Schizophrenia, Parkinson's Disease
Interventions
O-15 Water, 18F-Fluoro-L-dopa
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 90 Years
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 2:39 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease

NCT01474421
View directory record Official record
Conditions
Dyskinesias, Drug-induced
Interventions
AQW051, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
30 Years to 85 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Sacramento, California • Manhasset, New York • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2020 · Synced Oct 17, 2026, 2:39 AM EDT
Completed Phase 3 Interventional

Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's

NCT00363727
View directory record Official record
Conditions
Parkinson's Disease, Parkinson Disease, Dyskinesias
Interventions
ropinirole controlled-release (REQUIP CR) for RLS
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 70 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
69
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 17, 2026, 2:39 AM EDT
Completed Phase 2 Interventional Results available

Utility of [F-18] fluoroDOPA for Neonatal Hyperinsulinism

NCT00674440
View directory record Official record
Conditions
Congenital Hyperinsulinism, Hyperinsulinism, Persistent Hyperinsulinemic Hypoglycemia of Infancy, CHI, PHHI
Interventions
F-DOPA, PET scan
Drug · Radiation
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 18 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 9, 2022 · Synced Oct 17, 2026, 2:39 AM EDT
Completed Phase 4 Interventional Results available

A Study of L-DOPA for Depression and Slowing in Older Adults

NCT02744391
View directory record Official record
Conditions
Major Depressive Disorder, Dysthymia, Depression Not Otherwise Specified, Decreased Processing Speed, Decreased Gait Speed
Interventions
Levodopa
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
60 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Oct 17, 2026, 2:39 AM EDT
Completed Phase 2 Interventional

Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

NCT01173731
View directory record Official record
Conditions
Parkinson Disease, Dyskinesia, Drug-Induced, Levodopa
Interventions
AFQ056
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Sunnyvale, California • Englewood, Colorado • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Oct 17, 2026, 2:39 AM EDT